ATAI vs GH: Which Is the Better Buy in 2026?

Same yardstick, side by side (as of August 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. ATAI and GH share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined ATAI and GH exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

AtaiBeckley (Nasdaq: ATAI) is a clinical-stage biopharmaceutical company focused on psychedelic and next-generation therapies for depression, anxiety and other mental health conditions. Formed by the November 2025 combination of atai Life Sciences and Beckley Psytech, its lead asset is BPL-003 (intranasal mebufotenin, a 5-MeO-DMT formulation) for treatment-resistant depression, which posted positive Phase 2b data in mid-2025, holds FDA Breakthrough Therapy designation, and is heading into a two-study Phase 3 program in 2026. Other programs include VLS-01 for treatment-resistant depression (Phase 2 topline expected late 2026) and EMP-01 for social anxiety disorder.

Full ATAI guide

Guardant Health is a precision-oncology company that reads cancer signals from blood and tissue samples. Its business runs across three lines. Oncology, the largest, sells tests like Guardant360 (comprehensive genomic profiling that helps match patients to targeted therapies) and Guardant Reveal (a blood test for minimal residual disease, meaning traces of cancer left after treatment). Biopharma and Data sells testing, companion-diagnostic development, and real-world data to drugmakers. Screening is the newest and most-watched line: Shield is the first blood test to win full FDA approval as a primary screening option for colorectal cancer in average-risk adults 45 and older. In Q1 2026 the company reported ~$302 million in revenue, with oncology up 36% to ~$205 million on ~86,000 tests, biopharma and data at ~$53 million, and screening at ~$41.6 million on ~44,000 Shield tests (versus ~$5.7 million a year earlier).

Full GH guide

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

• ATAI drivers: BPL-003 Phase 3 catalyst; Diversified pipeline.
• GH drivers: Shield colorectal screening ramp; Core oncology growth and leverage.

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: ATAI is pre-commercial and unprofitable, so the stock is a binary bet on clinical and regulatory outcomes; a single failed Phase 3 readout could erase much of the equity value. For GH, guardant is unprofitable and cash-consumptive, so it depends on the Shield launch converting into durable, reimbursed volume rather than one-off wins.

Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick ATAI if you believe its drivers more; GH if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the ATAI and GH guides.

ATAI. As a clinical-stage biotech, ATAI has negligible revenue and posts steady quarterly net losses funded by its balance sheet. Traditional valuation multiples do not apply; the market value reflects the perceived probability and size of future drug approvals. The roughly $210 million cash position and runway into 2029 are central to how investors judge financing risk ahead of Phase 3 data.

GH. Figures are approximate and tied to the asOf date; verify live numbers before acting. GH trades on a high price-to-sales multiple typical of a fast-growing, pre-profit diagnostics company, so the valuation is driven by expected future growth rather than current earnings. The share price is volatile and moved sharply in mid-2026 on reimbursement news (including a July 2026 UnitedHealth coverage decision for Shield), which is why the timeline to 2027 cash-flow breakeven and the pace of Shield adoption matter more than any single quarter.

Headline figures (approximate, July 2026): ATAI shows revenue (recent quarter) ~$1M, net loss (recent quarter) ~$30M, cash & securities ~$210M, cash runway into 2029; GH shows revenue (q1 2026 quarterly) ~$302 million, up 48% year over year, 2026 revenue guidance (full year) ~$1.30 to $1.32 billion (~32 to 34% growth), adjusted ebitda (q1 2026) ~-$59 million loss (still unprofitable), cash and equivalents ~$1.2 billion at quarter end.

ATAI and GH are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined ATAI and GH exposure against your real portfolio. It is not an investment adviser.